SCHEMBL6740621

SCHEMBL6740621

O=c1c(C2=NS(=O)(=O)c3cc(O)ccc3N2)c(O)c2cc(F)ccc2n1Cc1ccncc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.57
NR1I2 O75469 1/20 0.57
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PLK1 P53350 3/20 0.37
PTGDR2 Q9Y5Y4 3/20 0.37
KDM4E B2RXH2 3/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
TAAR1 Q96RJ0 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
RECQL P46063 1/20 0.33
CASP6 P55212 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6686477 0.83 CYP2C9 (0.63) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6732332 0.83 CYP2C9 (0.61) CYP2C9NR1I2MAPK1HSD17B10PTGDR2
SCHEMBL6738280 0.83 CYP2C9 (0.65) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6690316 0.83 CYP2C9 (0.83) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6233389 0.80 MAPK1 (0.69) CYP2C9NR1I2MAPK1HSD17B10KDM4E
SCHEMBL3917989 0.78 CYP2C9 (0.42) CYP2C9NR1I2PLK1PTGDR2KDM4E
SCHEMBL6732912 0.76 MAPK1 (0.57) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL7131813 0.76 CYP2C9 (0.80) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6738807 0.76 CYP2C9 (0.72) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6693468 0.75 CYP2C9 (0.81) CYP2C9NR1I2MAPK1HSD17B10PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 CYP2C9 1218/4885NR1I2 1798/4885MAPK1 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.